Muthana Al Obaidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muthana Al Obaidi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aris E. Syntakas
Paediatric Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust , London
3 shared publications - Charalampia Papadopoulou
Paediatric Rheumatology, Great Ormond Street Hospital for Children, NHS Foundation Trust , London
3 shared publications - Adam P. Croft
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
2 shared publications - Ashirwad Merve
Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
2 shared publications - Christopher Mahony
Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK
2 shared publications - Clarissa Pilkington
Department of Paediatric Rheumatology, Great Ormond Street Hospital NHS Foundation Trust , London
2 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
IFN-related gene expression defines disease activity, organ involvement and treatment response in JDM
Objectives: To evaluate the relationship between IFN-related gene (IRG) expression and disease activity, organ involvement and serological subgroups in JDM and to assess its potential as a biomarker for disease monitoring and treatment response. Methods: Patients with JDM enrolled in a single-centre cohort were assessed using standardized clinical measures, including physician’s global assessment (PGA), Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and modified skin disease activity score. Associations between IRG expression and clinical features were analysed using correlation analyses and mixed-effects models. Longitudinal trajectories of disease activity were explored using latent class mixed models. Results: Seventy-four patients contributed 158 samples. Expression of type-I IRGs (IFI27, IFI44L, IFIT1, RSAD2, SIGLEC1) and CXCL10 was significantly higher in active disease and correlated with muscle and skin disease activity. IRG expression inversely correlated with CMAS and MMT8 and positively with mDAS. Distinct organ-specific associations were identified: CXCL9 expression was associated with interstitial lung disease, while IL-18 was associated with calcinosis, cutaneous ulceration and gastrointestinal involvement. Higher IRG expression was observed in patients with anti-MDA5 and anti-NXP2 autoantibodies. Longitudinal analyses demonstrated that IRG expression paralleled disease activity trajectories and decreased in patients achieving inactive disease, including those treated with baricitinib. Conclusion: IFN pathway activation is closely associated with disease activity and organ involvement in JDM. IRG expression reflects dynamic changes in disease status and may serve as a clinically useful biomarker for monitoring disease activity, stratifying patients by organ involvement and supporting response assessment to targeted therapies.
- 25 July 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Open AccessIFN-related gene expression defines disease activity, organ involvement and treatment response in JDM
Objectives: To evaluate the relationship between IFN-related gene (IRG) expression and disease activity, organ involvement and serological subgroups in JDM and to assess its potential as a biomarker for disease monitoring and treatment response. Methods: Patients with JDM enrolled in a single-centre cohort were assessed using standardized clinical measures, including physician’s global assessment (PGA), Childhood Myositis Assessment Scale (CMAS), Manual Muscle Testing (MMT8) and modified skin disease activity score. Associations between IRG expression and clinical features were analysed using correlation analyses and mixed-effects models. Longitudinal trajectories of disease activity were explored using latent class mixed models. Results: Seventy-four patients contributed 158 samples. Expression of type-I IRGs (IFI27, IFI44L, IFIT1, RSAD2, SIGLEC1) and CXCL10 was significantly higher in active disease and correlated with muscle and skin disease activity. IRG expression inversely correlated with CMAS and MMT8 and positively with mDAS. Distinct organ-specific associations were identified: CXCL9 expression was associated with interstitial lung disease, while IL-18 was associated with calcinosis, cutaneous ulceration and gastrointestinal involvement. Higher IRG expression was observed in patients with anti-MDA5 and anti-NXP2 autoantibodies. Longitudinal analyses demonstrated that IRG expression paralleled disease activity trajectories and decreased in patients achieving inactive disease, including those treated with baricitinib. Conclusion: IFN pathway activation is closely associated with disease activity and organ involvement in JDM. IRG expression reflects dynamic changes in disease status and may serve as a clinically useful biomarker for monitoring disease activity, stratifying patients by organ involvement and supporting response assessment to targeted therapies.
- Open Access
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Spatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- 9 August 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 84 (10) , 1706-1720
Open AccessSpatial transcriptomic analysis of muscle biopsy from patients with treatment-naive juvenile dermatomyositis reveals mitochondrial abnormalities despite disease-related interferon-driven signature
- Open Access
Spatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.
Open AccessSpatial transcriptomic analysis of muscle biopsy from treatment-naive juvenile dermatomyositis patients reveals mitochondrial abnormalities despite disease-related interferon driven signature
Objectives: This study aimed to investigate the spatial transcriptomic landscape of muscle tissue from treatment-naïve juvenile dermatomyositis (JDM) patients in comparison to healthy paediatric muscle tissue. Methods: Muscle biopsies from three JDM patients and three age-matched controls were analysed using the Nanostring GeoMx® Digital Spatial Profiler. Regions of interest were selected based on muscle fibres without immune cells, immune cell infiltration and CD68+ macrophage enrichment. Differential gene expression, pathway analysis and pathways clustering analysis were conducted. Key findings were validated in 19 cases of JDM using immunohistochemistry and chemical stains, and a bulk RNAseq dataset of four cases of JDM. Results: JDM muscle tissues exhibited significant interferon pathway activation and mitochondrial dysfunction compared to controls. A 15-gene interferon signature was significantly elevated in JDM muscle and macrophage-enriched regions, correlating with clinical weakness. In contrast, mitochondrial dysregulation, characterized by downregulated respiratory chain pathways, was present regardless of interferon activity or muscle strength. The interferon-driven and mitochondrial signatures were replicated in an independent RNAseq dataset from JDM muscle; lack of association between interferon signature and mitochondrial dysregulation was validated in 19 cases by conventional staining methods. Clustering analysis revealed distinct transcriptomic profiles between JDM and control tissues, as well as between JDM patients with varying clinical phenotypes. Conclusions: This study highlights mitochondrial dysfunction as a consistent pathological feature in JDM muscle, which may be independent of interferon-driven inflammation. These findings highlight the potential for mitochondrial-targeted therapies in JDM management and emphasise the need for further studies to explore their therapeutic value. KEY MESSAGES: What is already known on this topic Juvenile dermatomyositis (JDM) involves interferon-driven inflammation and immune-mediated muscle damage. Mitochondrial abnormalities in blood immune cells persist despite treatment and contribute to disease pathology. What this study adds Mitochondrial dysfunction is present in both muscle fibres and tissue-infiltrating immune cells within JDM muscle. These abnormalities are detectable even in clinically less severe muscle weakness. Degree of mitochondrial abnormality at transcript and protein level may be independent of strength of IFN-driven signal. Mitochondrial dysregulation detected at transcriptional level correlates with abnormal transcription of muscle (sarcomere) and the subcellular peroxisome organelle. How this study might affect research, practice, or policy Targeting mitochondrial dysfunction could enhance treatment outcomes for JDM, especially in patients whose disease is refractory to current therapies. Insights from this study support the development of stratification tools to detect aspects of pathology which are not tightly correlated with IFN-driven pathology.